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Autism is classified as a “pervasive devel-
opmental disorder”—pervasive because 
it affects many aspects of cognition and 
behavior and developmental because 
autistic symptoms emerge during devel-
opment from infancy or perhaps from 
birth. Yet, a key question about autism is 
at what stage during brain development 
does the primary lesion occur? Sev-
eral recent findings in genetic models of 
autism suggest that substantial improve-
ment in some behavioral or neurobiologi-
cal defects can result from gene replace-
ment or pharmacological treatment after 
“development” is largely complete. Does 
this mean that autism is less a fixed defect 
in development, and more a disorder of 
late postnatal development, plasticity, or 
even adult function? Here, we consider 
the role of genes and early development 
in autism, providing a context for consid-
eration of treatment strategies.
Genes and Autism
Autism is regarded as a highly genetic 
disorder, although the genes involved 
have proved difficult to identify (see 
Essay by D.H. Geschwind, page 391 of 
this issue). A focus on the genetic nature 
of autism provides a unique opportu-
nity to consider its pathophysiologi-
cal mechanisms. Perhaps surprisingly, 
indistinguishable autistic disorders can 
clearly be caused by many different 
genetic changes, a phenomenon gener-
ally referred to as genetic heterogeneity. 
The first genes implicated in autism were 
associated with broader syndromes that 
included autistic symptoms rather than 
with pure or nonsyndromic autism (for 
which the child psychiatrist Leo Kanner 
is generally credited with providing the 
original description). For instance, prom-
inent autistic symptoms accompany a 
genetic metabolic disorder called phe-
nylketonuria (PKU) (Fombonne, 1999). In 
addition, children with mutations in the 
genes associated with tuberous sclero-
sis (TSC1, TSC2) or in the PTEN tumor 
suppressor gene show prominent autis-
tic symptoms, although these patients 
would not generally be diagnosed with 
autism because they show broader 
symptoms (such as tumors or benign 
malformations, called hamartomata, of 
many structures including brain, skin, 
and kidney). Deletions of chromosome 
22q11 (the region normally associated 
with velo-cardiofacial syndrome) are 
seen in about 1% of autistic children 
but again are typically accompanied by 
other features as well (cleft palate, con-
genital heart disease). Inverted duplica-
tions of proximal chromosome 15q are 
also associated with autistic symptoms 
but often cause prominent mental retar-
dation as well.
Important clues about the mecha-
nisms underlying autism come from the 
monogenic disorders Rett’s syndrome 
and Fragile X syndrome (see Essay by 
Kelleher and Bear, page 401 of this 
issue). Rett’s syndrome, caused by 
mutations in the human MECP2 gene, 
which encodes the methyl-cytosine 
binding protein, occurs almost exclu-
sively in girls (mutations in this X-linked 
gene are lethal to males). Affected 
girls show normal development for 
1–2 years, followed by the appearance 
of stereotyped repetitive hand move-
ments and a regression of neurological 
and social skills. Similarly, one of the 
best-known disorders associated with 
autistic symptoms is the Fragile X syn-
drome. Males with Fragile X syndrome 
typically have developmental delays (for 
example, delays in walking or language) 
and somatic dysmorphology (for exam-
ple, large ears, a large head), and so 
Fragile X is generally not referred to as 
autism per se. Although there are many 
syndromic forms of autism, it is also 
important to stress that 40% to 60% 
of autistic children show some degree 
of mental retardation (Giacometti et al., 
2007), although measuring IQ in autism 
may pose challenges. Also, some pedi-
atric neurology clinics report that ~30% 
of autistic patients suffer from seizures 
(Fombonne, 1999).
As clinical genetic testing becomes 
more frequent, more autistic children will 
receive specific genetic diagnoses. The 
same genetic defects associated with 
broader syndromes are now recognized 
to cause a spectra of abnormalities, 
including those found in some higher-
functioning children with autism. For 
instance, deletion of 22q11 (Vorstman et 
al., 2006), Fragile X gene abnormalities, 
or milder MECP2 mutant alleles (Moretti 
and Zoghbi, 2006) are occasionally seen 
in children without the typical broader 
syndromes associated with these con-
ditions. Why similar genetic abnormali-
ties cause a range of phenotypes is an 
enduring mystery and may reflect the 
involvement of other genetic or nonge-
netic factors.
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Genetic studies are refining our understanding of neurodevelopmental mechanisms in autism. 
Some autism-related mutations appear to disrupt genes regulated by neuronal activity, which are 
especially important in development of the postnatal nervous system. Gene replacement studies 
in mice indicate that the developmental window to ameliorate symptoms may be wider than previ-
ously anticipated.
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One of the areas that has seen the most 
rapid recent progress in autism genet-
ics has come with the realization that 
up to 7%–10% of children with autism 
have a variety of de novo chromosomal 
deletions and duplications (Sebat et al., 
2007;Marshall et al., 2008; Kim et al., 
2008). These deletion syndromes typi-
cally cause a spectrum of phenotypes 
that includes autism. Some chromosome 
aberrations have been helpful in identi-
fying specific genes mutated in autism, 
and some of these genes appear to have 
brain-specific functions. For instance, X 
chromosome deletions implicated the 
NLGN3 and NLGN4 genes (Jamain et 
al., 2003) encoding neuroligins 3 and 4, 
which are synaptic adhesion molecules. 
Subsequent studies identified an NLGN4 
mutation inherited in a large family with 
many affected males showing mental 
retardation and/or autism (Laumonnier 
et al., 2004). These findings suggest that 
NLGN3 and NLGN4 gene mutations are 
causes, albeit rare, of autism, mental 
retardation, and potentially other neu-
ropsychiatric syndromes. The SHANK3 
gene, which encodes a cytoplasmic 
binding partner of the neuroligins, was 
also identified based on a chromosomal 
deletion (Durand et al., 2007). Chro-
mosome deletions (Kirov et al., 2007; 
Moessner et al., 2007) and translocations 
(Kim et al., 2008) involving the NRXN1 
neurexin gene, which encodes an extra-
cellular binding ligand for neuroligins, 
have implicated this gene in autism as 
well. Rare changes in CNTNAP2, encod-
ing contactin associated protein-like 2 (a 
neurexin superfamily member), are asso-
ciated with autism, and common alleles 
of CNTNAP2 may increase the risk of 
developing autism. Even these muta-
tions, which can affect the neuronal syn-
apse, tend not to be highly specific for 
“pure autism” but rather cause a broader 
mental retardation phenotype in some 
patients and pure autism in others.
Why do many mutations associated 
with autism occur de novo, meaning 
they are present in the child but not in 
the parents or earlier ancestors? This is 
actually not surprising. Autistic children 
rarely marry and have children, so that 
the condition is subject to “negative 
evolutionary selection,” with affected 
patients having decreased fertility. This 
negative selection means that for muta-
tions to be observed in the population 
they must frequently occur as de novo 
mutations. Such negative evolution-
ary selection is common to mutations 
associated with other severe diseases, 
especially those of childhood, for exam-
ple mental retardation, epilepsy, or con-
genital heart disease (Lupski, 2007). 
A recent study focused on identifying 
autosomal recessive loci in pedigrees 
with autism and recent shared ancestry 
(Morrow et al., 2008). Autosomal reces-
sive mutations, like sporadic mutations, 
also frequently reduce reproductive fit-
ness. In this study, consistent with the 
finding of copy number variations (CNVs) 
in autism, multiple heterogeneous loci 
were implicated, but these loci represent 
potential inherited causes. Hence, by 
tracing shared ancestry this approach 
may provide an important way to iden-
tify inherited loci in heterogeneous neu-
rodevelopmental conditions that reduce 
reproductive fitness.
Is it unusual that mutant forms of many 
different genes cause an overlapping or 
indistinguishable autistic phenotype? On 
the contrary, it appears to be the rule, 
at least for neurological disorders of 
the cerebral cortex, such as dementia, 
mental retardation, or epilepsy. Disor-
ders that affect the cerebral cortex and 
its associated forebrain neural systems 
may uniquely define this genetic hetero-
geneity, perhaps because the forebrain 
requires many genes (likely >10,000) for 
normal development and function, yet the 
plasticity of forebrain structures appears 
tailor-made to redistribute and remap 
critical functions in response to pertur-
bation. Hence, the cerebral cortex may 
provide essentially a “plastic reserve” to 
ameliorate genetic defects, which in turn 
results in there being a small number of 
stable, recognizable, abnormal states 
that multiple mutant genes converge 
upon.
Gleaning Cellular Mechanisms from 
Genetics
When surveying the cellular mecha-
nisms that flow from the genetic defects 
associated with autism, one of the most 
striking revelations is the important role 
of genes that encode proteins of the 
neuronal synapse (Zoghbi, 2003) (Figure 
1). NLGN3/NLGN4 and NRXN1 encode 
a ligand-receptor pair that mediates 
Figure 1. The Potential Relationships of Autism Genes to Synaptic Function
Synaptic activity stimulates signaling pathways that ultimately result in the binding in the nucleus of tran-
scription factors to specific DNA sequences necessary to activate target genes, which in turn modify syn-
aptic efficacy. Gene mutations associated with autism affect synaptic proteins such as neuroligins 3 and 
4 (NLGN3, NLGN4), neurexin 1 (NRXN1), contactin associated protein-like 2 (CNTNAP2), and SHANK3. 
These proteins include adhesion molecules of the synapse or cytoplasmic molecules that associate 
with synaptic receptors. In addition, some genes, such as MECP2 and ARX, which encode proteins that 
regulate DNA transcription, are associated with autistic features when mutated. Moreover, some of the 
targets of these activity-dependent transcription factors are mutated in recessive autism. Some autism 
mutations appear to involve not the coding sequence of genes but rather noncoding sequences that 
may regulate patterns of gene transcription. For example, PCDH10 and CNTN3 encode proteins that are 
potentially associated with the synapse yet autism mutations do not alter the coding part of these genes. 
Together these data suggest that heterogeneous causes of autism may be associated with alterations in 
activity-dependent synaptic plasticity.
synaptic development, and SHANK3 
encodes a cytoplasmic adaptor pro-
tein that binds to neuroligin (Durand et 
al., 2007) . On the other hand, synaptic 
activity-related signals are transduced 
into alterations in protein synthesis within 
the synaptic spine, and several other 
genes associated with autism medi-
ate these changes in protein synthesis, 
including FMR1, PTEN, and TSC1/TSC2 
(see Essay by Kelleher and Bear, page 
401 of this issue). Hence, the importance 
of this synaptic activity-related response 
is very clear. Interestingly, a recent study 
suggested that the synapse-promoting 
function of neuroligin 1 in mice is depen-
dent on synaptic activity (Chubykin et 
al., 2007). Autism genes identified in 
another genome-wide study showed 
significant association with those identi-
fied in an independent screen for genes 
regulated by neuronal activity or by tran-
scription factors regulated by neuronal 
activity (Morrow et al., 2008). In this 
study, the transcription factor MEF2 was 
found to regulate two genes implicated 
in the whole-genome study of autism 
pedigrees, namely PCDH10 (protocad-
herin10, another neuronal cell adhesion 
protein) and DIA1 (deleted-in-autism1, 
also known as c3orf58, a new protein 
found in the Golgi) (Figure 1). Finally, 
consistent with the association of activ-
ity-regulated genes with autism, a con-
ditional MEF2c knockout mouse has 
abnormalities in synaptic maturation and 
behavior related to Rett’s syndrome, an 
autism-related disorder (Li et al., 2008).
Other genes associated with autism 
seem to affect neuronal excitability, 
or the ratio of excitation to inhibition 
(Rubenstein and Merzenich, 2003). 
Indeed, mutations in neuroligins appear 
to affect the balance between excitatory 
and inhibitory synapses (Tabuchi et al., 
2007). MeCP2 mutations in mice also 
appear to regulate the balance of excit-
atory and inhibitory synapses (Chao et 
al., 2007; Dani et al., 2005). Furthermore, 
evidence is accumulating that several 
genes associated with autism play roles 
in the development of cortical inhibitory 
interneurons including c-Met (Campbell 
et al., 2006, 2007), DLX (Hamilton et al., 
2005), and ARX, where rare, partially 
inactivating mutations cause mental 
retardation or autism (Kato et al., 2004; 
Turner et al., 2002). A common theme of 398 Cell 135, October 31, 2008 ©2008 Elsethese studies is that autism may relate 
less to generic synaptic function and 
more to levels of excitation or inhibition, 
and the balance between the two.
One unifying hypothesis, consistent 
with current findings, is that genes asso-
ciated with autism may encode proteins 
that mediate activity-dependent changes 
in neuronal function (Hong et al., 2005; 
Zoghbi, 2003). These activity-dependent 
changes require gene transcription and 
ultimately result in synaptic plastic-
ity, learning, and memory formation. 
A recent analysis of recessive autism 
mutations shows that 5% of these rep-
resent homozygous deletions, com-
pletely removing both copies of specific 
gene segments (Morrow et al., 2008). 
Homozygous deletions often occur near 
activity-regulated genes, either removing 
the gene entirely or sometimes remov-
ing only noncoding sequences outside 
the region of the gene that codes for 
the protein. In addition, two other stud-
ies have implicated noncoding variants 
(potentially with regulatory activity) with 
autism (Campbell et al., 2006; Sutcliffe 
et al., 2005). These presumptive regula-
tory mutations may ultimately complete 
an “autism pathway” by showing autism-
associated disruptions at each step from 
the synapse to activity-dependent gene 
activation. Hence, autism may reflect a 
disorder of regulation of gene expression 
level under specific circumstances, such 
as activity-dependent learning. This may 
explain the sometimes milder syndrome 
of autism compared to mental retarda-
tion, where specific genes are typically 
inactivated completely by mutations 
that disrupt those parts of the gene that 
encode the protein.
The Specificity of Autism
Whereas synaptic changes presumably 
underlie all forms of learning, the synap-
tic view of autism does not provide an 
explanation for the preferential loss of 
linguistic and social functions in autism. 
Although there is little data on this point, 
several hypotheses seek to explain this 
specificity. In one view, specific neural 
circuits essential for social behavior (Bel-
monte and Bourgeron, 2006; Levitt et al., 
2004; Rubenstein and Merzenich, 2003) 
are preferentially disrupted by muta-
tions in either synaptic or other proteins. 
For example, vasopressin and oxytocin vier Inc.regulate social behavior in mammals 
(Caldwell et al., 2008; Campbell, 2008), 
and hence synaptic defects in oxytocin 
and vasopressin pathways could cause 
defects in human social behavior (Insel 
and Young, 2001). Such a social learning 
model may also relate to the observed 
male-female differences in autism preva-
lence (boys are typically affected at least 
four times more commonly than girls). 
The basis for this male-female difference 
in autism prevalence is not understood, 
but one hypothesis is that the male brain 
may be built in such a way as to be par-
ticularly susceptible to abnormalities 
in pathways that control social behav-
ior (Baron-Cohen and Belmonte, 2005; 
Gomot et al., 2006). In addition, some of 
the cognitive features of higher-function-
ing autistic patients (with splinter skills 
or relatively spared abilities) or even the 
outstanding gifts of so-called autistic 
savants remain to be explained.
Another hypothesis to explain the 
specificity of autism for affecting lan-
guage and social behavior holds that 
these are simply the most difficult tasks 
ever learned by the human brain, so that 
mild global defects in synaptic function 
may be sufficient to impair them. Lan-
guage acquisition, at ~2 years of age 
is one of the last developmental mile-
stones, whereas learning about social 
relationships continues into adulthood. 
The late appearance of these landmarks 
may reflect the complex circuitry they 
require, which may be susceptible to 
subtle defects that spare simpler tasks. 
Alternatively, genes implicated in autism 
may include those that have been under 
recent evolutionary selection (Baron 
Cohen and Belmonte, 2005). After all, the 
ability of humans to live in large social 
groupings—that is, civilization—was a 
recent evolutionary development, occur-
ring only after the appearance of ana-
tomically modern humans, and probably 
as recently as 50,000 years ago. There is 
evidence that some genes (Williamson et 
al., 2007) and genomic regions (16p11.2) 
in which mutations cause autism show 
signatures of recent evolutionary selec-
tion.
A consideration of autism as an evo-
lutionarily recent disorder also suggests 
that disruption of evolutionarily new parts 
of the brain may relate to autism. Among 
these more newly evolved regions of the 
brain is the frontal cortex (Hill and Walsh, 
2005), and recent evidence shows that 
disorders of frontal cortex development 
produce social defects. For example, the 
secreted signaling protein Fgf17 is essen-
tial for normal development of the frontal 
cortex of mice (Cholfin and Rubenstein, 
2007). Fgf17 mutations in mice result in 
defects in social behavior, which may 
be a model for autism (Scearce Levie et 
al., 2007). Fgf17 signaling uses receptor 
tyrosine kinases and therefore is likely to 
be modulated by proteins encoded by 
TSC1, TSC2, and PTEN; perhaps muta-
tions in this signaling pathway have early 
effects on frontal cortex patterning, as 
well as later effects on synaptic signal-
ing, each contributing susceptibility to 
autism.
Apparent Reversal of Neurobiologi-
cal Defects in the Adult
A remarkable finding in some recently 
studied animal models of autistic symp-
toms has been the surprising degree to 
which autistic symptoms have been 
apparently reversed or ameliorated by 
replacing or modulating gene function 
after birth or even in the adult. The first 
example of this came with a Drosophila 
model of Fragile X syndrome (McBride 
et al., 2005). Normally, the mutant 
flies have a defect in social/courtship 
learning and also have defects in the 
axons of neurons clustered in a brain 
region known as the mushroom body. 
The Fragile X disease pathway was 
modulated by administration of several 
drugs including metabotropic gluta-
mate antagonists that can decrease the 
excessive protein translation caused by 
mutations in FMR (the protein mutated 
in Fragile X syndrome; see the Essay 
by Kelleher and Bear, page 401 of this 
issue) or even using lithium carbonate, 
which modulates downstream signal-
ing of the Fragile X pathway through 
the kinase GSK-3β. Remarkably, in 
flies born with fixed defects in social 
behavior the phenotype could be res-
cued almost completely in adulthood 
by administration of metabotropic 
glutamate antagonists or even lithium 
(McBride et al., 2005).
An even more remarkable example of 
the reversibility of autism-related genetic 
and neurobiological defects comes from 
the study of mouse models of Rett’s syn-drome. The Bird and Jaenisch labs cre-
ated mice that lacked MeCP2, and when 
the mice were born they developed the 
typical symptoms of Rett’s syndrome 
(Giacometti et al., 2007; Guy et al., 2007). 
Remarkably, reinstating the MeCP2 gene 
after birth caused partial (Giacometti et 
al., 2007) or seemingly complete (Guy et 
al., 2007) resolution of the abnormalities. 
These findings suggest that MECP2 is 
not essential for the earliest wiring of the 
nervous system but instead is required 
later for activity-dependent processes. 
This is consistent with the normal devel-
opment of Rett’s syndrome in girls until 
18–24 months of age, and it highlights 
the potential for reversing the symptoms 
of Rett’s syndrome in humans, if effec-
tive therapies can be found.
The apparent phenotypic reversibil-
ity of some autism-associated genetic 
defects suggests a refinement of autism 
as a paradigmatic “developmental dis-
order,” as it may be partially distinct 
from mental retardation. Development of 
the nervous system is characterized by 
several phases that occur in sequence. 
Early stages of neuronal production, 
axonal outgrowth, and initial connectiv-
ity are driven by intrinsic genetic pro-
grams, which are largely independent 
of synaptic activity (Sur and Ruben-
stein, 2005). At later stages, refine-
ment of synapses relies on neuronal 
activity, which in turn induces activity-
dependent transcriptional changes 
that underlie synaptic plasticity and 
ultimately learning (Hong et al., 2005). 
Mental retardation often reflects muta-
tions in genes that sculpt early devel-
opment of brain architecture, leading 
to fixed defects in connectivity. On the 
other hand, defects in autism appear 
more closely tied to later developmental 
steps that depend on synaptic activity 
and activity-dependent changes. This 
may explain the later age of diagnosis of 
autism, the preferential effects on skills 
that appear later in childhood like lan-
guage and social behavior, and perhaps 
the greater likelihood of improvement in 
some fortunate children. The later onset 
of autism-specific defects in synaptic 
activity is an optimistic sign that, if we 
can develop medications to modulate 
these synaptic changes, we may be 
able to provide better therapies for this 
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